Natco Pharma Shares Gain 2.5% Following Launch of Generic Semaglutide Injection in India

Natco Pharma Shares Rise 2.5% as Company Prepares to Launch Generic Semaglutide in India

On March 30, Natco Pharma shares were trading 2.5% higher following the company's announcement of the imminent launch of its generic Semaglutide Injection (multi-dose vials) in the Indian market. This move comes on the heels of the patent expiry of Novo Nordisk's Semaglutide in India.

Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market generic Semaglutide in India for multi-dose vials and pen device. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

The company plans to launch Semaglutide injection in the form of multi-dose vials of strengths 2mg/1.5ml, 4mg/3ml, and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. The monthly maximum retail prices (MRP) for multi-dose vials will be Rs 1,290 for 2 mg/1.5ml and 4mg/3ml, and Rs 1,750 for 8mg/3ml. The MRP for the pen device will be Rs 4,000, Rs 4,200, and Rs 4,500 per month for the respective strengths.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Natco Pharma is the first company to offer generic Semaglutide in multi-dose vials with customized syringes. The company is also offering the product to third parties for co-marketing, citing its affordability as a key differentiator. The generic version is approximately 70% cheaper than the pen device and 90% cheaper than the innovator's brand, making it the most affordable GLP-1 currently in the Indian market.

The launch of generic Semaglutide in India is expected to increase patient accessibility to GLP-1 therapy and improve long-term compliance for patients. Natco Pharma's shares were trading 2.6% higher at Rs 962.65 apiece at 11:17 am on March 20, while Dr Reddy's Laboratories shares were trading 1.5% higher, and Emcure Pharma shares were trading 0.5% higher on the same day.